Skip to main content

Generalized Anxiety Disorder

  • Reference work entry
  • First Online:
Encyclopedia of Psychopharmacology


Anxiety neurosis; Free-floating anxiety; GAD


Generalized anxiety disorder (GAD) is characterized by an excessive and inappropriate worrying that is persistent and not restricted to particular circumstances. Patients have physical anxiety symptoms (such as tachycardia and tremor) and key psychological symptoms, including restlessness, fatigue, difficulty in concentrating, irritability, and disturbed sleep. The disorder is common and disabling; a recent review of epidemiological studies in Europe suggests a 12-month prevalence of between 1.7 % and 3.75 % (being more common in old age), and the associated functional impairment is similar to that with major depression. However, many of those who might benefit from treatment are not recognized or treated, which is disappointing, as a broad range of evidence-based treatments is available.

Role of Pharmacotherapy

Efficacy in Acute Treatment

Current evidence-based guidelines for the pharmacological management of patients...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,099.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions


  • Baldwin DS (2008) Room for improvement in the pharmacological treatment of anxiety disorders. Curr Pharm Des 14:3482–3491

    Article  CAS  PubMed  Google Scholar 

  • Baldwin DS, Ajel K (2007) The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 3:185–191

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Baldwin DS, Anderson IM, Nutt DJ et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for psychopharmacology. J Psychopharmacol 19:567–596

    Article  CAS  PubMed  Google Scholar 

  • Baldwin DS, Montgomery SA, Nil R et al (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73–84

    Article  CAS  PubMed  Google Scholar 

  • Baldwin DS, Schweitzer E, Lu Y, Lyndon G (2012) Does early improvement predict end-point response in patients with generalized anxiety disorder? Eur Neuropsychopharmacol 22:137–142

    Article  CAS  PubMed  Google Scholar 

  • Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009) How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269–275

    Article  CAS  PubMed  Google Scholar 

  • Baldwin DS, Woods R, Lawson TD (2011) Efficacy of treatments for generalized anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199

    Article  PubMed  Google Scholar 

  • Bandelow B, Seidler-Brandler U, Becker A et al (2007) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatr 8:175–187

    Article  Google Scholar 

  • Bandelow B, Zohar J, Hollander E et al (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248–312

    Article  PubMed  Google Scholar 

  • Chessick CA, Allen MH, Thase M et al (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 3, CD006115

    PubMed  Google Scholar 

  • Hidalgo RB, Tupler LA, Davidson JRT (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864–872

    Article  CAS  PubMed  Google Scholar 

  • Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM (2008) Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 42:1176–1184

    Article  PubMed  Google Scholar 

  • Rickels K, Shivitz TM, Ramey TS, Weaver JJ, Knapp LR, Miceli JJ (2012) Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychipharmacol 27:142–150

    Article  Google Scholar 

  • Stein MB, Schork NJ, Gelernter J (2008) Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacology 33:312–319

    Article  CAS  PubMed  Google Scholar 

  • Tyrer P, Baldwin DS (2006) Generalised anxiety disorder. Lancet 368:2156–2166

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Malcolm Lader .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Lader, M. (2015). Generalized Anxiety Disorder. In: Stolerman, I.P., Price, L.H. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg.

Download citation

Publish with us

Policies and ethics